PRMT7-IN-2

• Description :

  PRMT7-IN-2 (A33) is a selective PRMT7 inhibitor with an IC50 of 0.50 μM. PRMT7-IN-2 arrests cell cycle at G0/G1 phase, induces cell apoptosis, and inhibits cell growth in vivo and in vitro. PRMT7-IN-2 decreases the monomethylarginine level of PRMT7, increases expression of epithelial marker (E-cadherin, and reduces expression of mesenchymal markers such as N-cadherin, Vimentin, and ZEB2[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Histone Methyltransferase

• Related Pathways :

  Apoptosis; Epigenetics

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  98.26

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  COC1=CC(C2=NC3=C(C(NC4=CC=C(C5=C4)N=C(C=C5N)C)=N2)SC=C3)=CC(OC)=C1OC

• Molecular Formula :

  C25H23N5O3S

• Molecular Weight :

  473.55

• References & Citations :

  [1]Li J, et al. Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2025 Apr 24;68 (8) :8244-8268.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3058094-83-7]